{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+buffer&page=2",
    "query": {
      "intervention": "Formulation buffer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+buffer&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T11:26:49.510Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00833495",
      "title": "Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Prednisolone Acetate 0.12% (Pred Mild®)",
          "type": "DRUG"
        },
        {
          "name": "FOV1101-00",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone Acetate 1% (Pred Forte®)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fovea Pharmaceuticals SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2009-01",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2012-03-09",
      "last_synced_at": "2026-09-03T11:26:49.510Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00833495"
    },
    {
      "nct_id": "NCT00292942",
      "title": "Study of the Safety of Intravenous Artesunate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria",
        "Malaria, Cerebral"
      ],
      "interventions": [
        {
          "name": "Intravenous Artesunate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 26,
      "start_date": "2006-06-12",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2018-10-25",
      "last_synced_at": "2026-09-03T11:26:49.510Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00292942"
    },
    {
      "nct_id": "NCT03843710",
      "title": "31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "Gold Nanocrystals",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clene Nanomedicine",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "35 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2020-03",
      "completion_date": "2022-03",
      "has_results": false,
      "last_update_posted_date": "2023-04-03",
      "last_synced_at": "2026-09-03T11:26:49.510Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03843710"
    },
    {
      "nct_id": "NCT02277197",
      "title": "Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Squamous Cell of Head and Neck",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Squamous Cell Carcinoma, Head And Neck"
      ],
      "interventions": [
        {
          "name": "Ficlatuzumab",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "James J Lee",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2015-08",
      "completion_date": "2018-02",
      "has_results": false,
      "last_update_posted_date": "2019-04-18",
      "last_synced_at": "2026-09-03T11:26:49.510Z",
      "location_count": 3,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02277197"
    },
    {
      "nct_id": "NCT05227300",
      "title": "Buffered vs. Unbuffered Local Anesthesia in Mandibular Molars Diagnosed With Symptomatic Irreversible Pulpitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Symptomatic Irreversible Pulpitis"
      ],
      "interventions": [
        {
          "name": "Onset Sodium Bicarbonate Inj., 8.4%, USP Neutralizing Additive Solution",
          "type": "DRUG"
        },
        {
          "name": "2% lidocaine with 1:100,000 epinephrine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-02-14",
      "completion_date": "2022-06-30",
      "has_results": true,
      "last_update_posted_date": "2024-05-14",
      "last_synced_at": "2026-09-03T11:26:49.510Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05227300"
    },
    {
      "nct_id": "NCT05528588",
      "title": "Furoscix in Heart Failure Patients With Diuretic Resistance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Furoscix",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Diuretic Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 70,
      "start_date": "2023-06-02",
      "completion_date": "2024-07-01",
      "has_results": true,
      "last_update_posted_date": "2025-07-16",
      "last_synced_at": "2026-09-03T11:26:49.510Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05528588"
    },
    {
      "nct_id": "NCT07142278",
      "title": "DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Alzheimer Disease (AD)",
        "Preclinical Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "DUVAX 200 µg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DUVAX 400 µg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Adjuvant only)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Nuravax, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "40 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2026-10-20",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-09-03T11:26:49.510Z",
      "location_count": 1,
      "location_summary": "Miami Lakes, Florida",
      "locations": [
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07142278"
    },
    {
      "nct_id": "NCT03191383",
      "title": "A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV vaccine (GSK3003891A) formulation 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV vaccine (GSK3003891A) formulation 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV vaccine (GSK3003891A) formulation 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Formulation buffer S9b)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2017-07-11",
      "completion_date": "2017-07-14",
      "has_results": false,
      "last_update_posted_date": "2018-10-15",
      "last_synced_at": "2026-09-03T11:26:49.510Z",
      "location_count": 3,
      "location_summary": "Newton, Kansas • Syracuse, New York • Ellensburg, Washington",
      "locations": [
        {
          "city": "Newton",
          "state": "Kansas"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "Ellensburg",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03191383"
    },
    {
      "nct_id": "NCT00849459",
      "title": "Gene Therapy in Treating Women With Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "adenovirus-mediated human interleukin-12",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Max Sung",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 3,
      "start_date": "2008-08",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2017-01-11",
      "last_synced_at": "2026-09-03T11:26:49.510Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00849459"
    },
    {
      "nct_id": "NCT05500417",
      "title": "Safety and Immunogenicity of CJCV2 With and Without ALFQ",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Campylobacter Infection"
      ],
      "interventions": [
        {
          "name": "ALFQ",
          "type": "DRUG"
        },
        {
          "name": "CJCV2",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 59,
      "start_date": "2022-09-13",
      "completion_date": "2025-01-02",
      "has_results": true,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-09-03T11:26:49.510Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05500417"
    }
  ]
}